MEDI3185 Biosimilar – Anti-Stromal cell-derived factor 1 receptor mAb – Research Grade

Description of MEDI3185 Biosimilar - Anti-Stromal cell-derived factor 1 receptor mAb - Research Grade

Title: Introduction to MEDI3185 Biosimilar – Anti-Stromal cell-derived factor 1 receptor mAb – Research Grade

MEDI3185 Biosimilar is a monoclonal antibody (mAb) that specifically targets the stromal cell-derived factor 1 receptor (CXCR4). This biosimilar is being developed as a potential therapeutic agent for various diseases, including cancer and inflammatory disorders. In this article, we will discuss the structure, activity, and potential applications of MEDI3185 Biosimilar in detail.

Structure of MEDI3185 Biosimilar

MEDI3185 Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL). The variable domains of MEDI3185 Biosimilar are responsible for its specificity towards CXCR4.

Activity of MEDI3185 Biosimilar

CXCR4 is a G protein-coupled receptor that is involved in various biological processes, including cell migration, proliferation, and survival. It is also known to play a crucial role in the development and progression of cancer. MEDI3185 Biosimilar binds to CXCR4 with high affinity and blocks its interaction with its ligand, stromal cell-derived factor 1 (SDF-1). This prevents the activation of downstream signaling pathways that are involved in cancer progression. Additionally, MEDI3185 Biosimilar also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CXCR4-expressing cells, leading to their destruction.

Applications of MEDI3185 Biosimilar

1. Cancer treatment: The overexpression of CXCR4 has been observed in various types of cancer, including breast, lung, and pancreatic cancer. MEDI3185 Biosimilar has shown promising results in preclinical studies as a potential therapeutic agent for these cancers. It has been found to inhibit tumor growth and metastasis by targeting CXCR4-expressing cancer cells. Additionally, its ability to induce ADCC and CDC can enhance its anti-tumor activity.

2. Inflammatory disorders: CXCR4 is also involved in the recruitment of inflammatory cells to the site of inflammation. MEDI3185 Biosimilar has been shown to reduce the infiltration of inflammatory cells in animal models of rheumatoid arthritis and multiple sclerosis. This makes it a potential candidate for the treatment of these disorders.

3. Stem cell mobilization: CXCR4 plays a crucial role in the mobilization of hematopoietic stem cells from the bone marrow into the peripheral blood. MEDI3185 Biosimilar has been found to block this interaction between CXCR4 and SDF-1, resulting in the release of stem cells into the blood. This can be beneficial for patients undergoing stem cell transplantation.

4. Combination therapy: MEDI3185 Biosimilar has also been investigated in combination with other anti-cancer agents, such as chemotherapeutic drugs and immune checkpoint inhibitors. These studies have shown that MEDI3185 Biosimilar can enhance the efficacy of these agents by targeting CXCR4-expressing cancer cells.

Conclusion

MEDI3185 Biosimilar is a promising therapeutic agent that specifically targets CXCR4. Its unique mechanism of action and potential applications in various diseases make it a valuable addition to the current treatment options. Further clinical studies are required to establish its safety and efficacy in humans. However, MEDI3185 Biosimilar has the potential to become a valuable tool in the fight against cancer and other inflammatory disorders.